108 related articles for article (PubMed ID: 2526211)
1. Effect of several kinds of drugs on the development of autoimmunity in MRL/Mp-lpr/lpr mice; lack of correlation between the suppression of autoantibody production and prevention of autoimmune disease.
Mihara M; Ohsugi Y
J Pharmacobiodyn; 1989 Feb; 12(2):100-6. PubMed ID: 2526211
[TBL] [Abstract][Full Text] [Related]
2. A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice.
Mihara M; Takagi N; Urakawa K; Moriya Y; Takeda Y
Int Arch Allergy Immunol; 1997 Aug; 113(4):454-9. PubMed ID: 9250591
[TBL] [Abstract][Full Text] [Related]
3. Effect of methotrexate treatment on the onset of autoimmune kidney disease in lupus mice.
Mihara M; Katsume A; Takeda Y
Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2177-81. PubMed ID: 1423777
[TBL] [Abstract][Full Text] [Related]
4. An immunomodulating anti-rheumatic drug, lobenzarit disodium (CCA): inhibition of polyclonal B-cell activation and prevention of autoimmune disease in MRL/Mp-lpr/lpr mice.
Mihara M; Nakano T; Ohsugi Y
Clin Immunol Immunopathol; 1987 Dec; 45(3):366-74. PubMed ID: 3500002
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of autoimmune MRL/Mp-lpr/lpr mice with cholera toxin plus irradiation. Combined treatment of autoimmune MRL/l mice.
Fan JL; Himeno K; Hussain A; Nomoto K
Biotherapy; 1989; 1(2):97-102. PubMed ID: 2641464
[TBL] [Abstract][Full Text] [Related]
6. CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice.
Takiguchi M; Murakami M; Nakagawa I; Saito I; Hashimoto A; Uede T
Life Sci; 2000; 66(11):991-1001. PubMed ID: 10724446
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT).
Karussis DM; Vourka-Karussis U; Lehmann D; Abramsky O; Ben-Nun A; Slavin S
Clin Exp Immunol; 1995 Apr; 100(1):111-7. PubMed ID: 7697909
[TBL] [Abstract][Full Text] [Related]
8. Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis.
Shiraki M; Fujiwara M; Tomura S
Clin Exp Immunol; 1984 Feb; 55(2):333-9. PubMed ID: 6607792
[TBL] [Abstract][Full Text] [Related]
9. Effect of cyclophosphamide on lymphokine production in MRL/lpr.Yaa mice.
Kamada H; Takaoka Y; Kitagaki K; Nagai H
Inflamm Res; 1995 Nov; 44(11):491-8. PubMed ID: 8597884
[TBL] [Abstract][Full Text] [Related]
10. MRL mice produce anti-Su autoantibody, a specificity associated with systemic lupus erythematosus.
Treadwell EL; Cohen P; Williams D; O'Brien K; Volkman A; Eisenberg R
J Immunol; 1993 Jan; 150(2):695-9. PubMed ID: 8419494
[TBL] [Abstract][Full Text] [Related]
11. Thymic influences on autoimmunity in MRL-lpr mice.
Wofsy D; Ledbetter JA; Roubinian JR; Seaman WE; Talal N
Scand J Immunol; 1982 Jul; 16(1):51-8. PubMed ID: 6981841
[TBL] [Abstract][Full Text] [Related]
12. Regulation of anti-Sm autoantibodies by the immunoglobulin heavy chain locus.
Halpern MD; Craven SY; Cohen PL; Eisenberg RA
J Immunol; 1993 Dec; 151(12):7268-72. PubMed ID: 8258724
[TBL] [Abstract][Full Text] [Related]
13. Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRL/MP-lpr/lpr mice.
Jabs DA; Kuppers RC; Saboori AM; Burek CL; Enger C; Lee B; Prendergast RA
Cell Immunol; 1994 Mar; 154(1):66-76. PubMed ID: 7907009
[TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of autoimmune disease and coronary vasculitis in the MRL-lpr/lpr mouse model of systemic lupus erythematosus.
Gu L; Weinreb A; Wang XP; Zack DJ; Qiao JH; Weisbart R; Lusis AJ
J Immunol; 1998 Dec; 161(12):6999-7006. PubMed ID: 9862736
[TBL] [Abstract][Full Text] [Related]
15. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
Mannoor K; Matejuk A; Xu Y; Beardall M; Chen C
J Immunol; 2012 Apr; 188(8):3628-38. PubMed ID: 22407922
[TBL] [Abstract][Full Text] [Related]
16. Effects of immunomodulating treatment on autoimmune sialadenitis in MRL/Mp-lpr/lpr mice.
Jonsson R; Tarkowski A; Bäckman K
Agents Actions; 1988 Dec; 25(3-4):368-74. PubMed ID: 3218611
[TBL] [Abstract][Full Text] [Related]
17. Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease.
Bartlett RR; Popovic S; Raiss RX
Scand J Rheumatol Suppl; 1988; 75():290-9. PubMed ID: 3238364
[TBL] [Abstract][Full Text] [Related]
18. Effects of castration and sex hormones on immune clearance and autoimmune disease in MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice.
Shear HL; Wofsy D; Talal N
Clin Immunol Immunopathol; 1983 Mar; 26(3):361-9. PubMed ID: 6872348
[TBL] [Abstract][Full Text] [Related]
19. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.
Atkinson C; Qiao F; Song H; Gilkeson GS; Tomlinson S
J Immunol; 2008 Jan; 180(2):1231-8. PubMed ID: 18178863
[TBL] [Abstract][Full Text] [Related]
20. Induction of autoantibodies in normal mice by injection of nucleobindin and natural occurrence of antibodies against nucleobindin in autoimmune MRL/lpr/lpr mice.
Kanai Y; Takeda O; Miura K; Amagai M; Kaneko T; Kubota T; Kanai Y; Tanuma S; Kurosawa Y
Immunol Lett; 1995 Feb; 45(1-2):35-42. PubMed ID: 7622185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
